Related Experiment Video
Updated: Feb 2, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study
Martin H Voss1, Albert Reising2, Yuan Cheng2
1Memorial Sloan Kettering Cancer Center, New York, NY, USA.
This study enhances the Memorial Sloan Kettering Cancer Center (MSKCC) risk model for metastatic renal-cell carcinoma by incorporating tumor genomics. Adding BAP1, PBRM1, and TP53 mutation status improves prognostic accuracy for overall survival and progression-free survival.
Area of Science:
- Oncology
- Genomics
- Cancer Prognostics
Background:
- The Memorial Sloan Kettering Cancer Center (MSKCC) risk model is a standard prognostic tool for metastatic renal-cell carcinoma (mRCC).
- Current models do not integrate tumor genomics, despite known prognostic value of mutations like BAP1 and PBRM1 in renal-cell carcinoma.
- There is a need to enhance prognostic models for mRCC by incorporating genomic data.
Purpose of the Study:
- To investigate if adding the mutation status of key prognostic genes to the MSKCC risk model improves its prognostic performance in mRCC.
- To develop a genomically annotated risk model for mRCC.
Main Methods:
- Retrospective cohort study using two independent clinical trial datasets (COMPARZ and RECORD-3) of treatment-naive mRCC patients receiving tyrosine kinase inhibitors.
- Somatic mutations in six candidate genes (BAP1, PBRM1, TP53, TERT, KDM5C, SETD2) were analyzed using next-generation sequencing in the training cohort.
- Prognostic value of mutations was assessed, and significant genes were incorporated into the MSKCC model to create a genomically annotated version, which was validated.
Main Results:
- In the training cohort, mutations in BAP1, TP53, and PBRM1 showed independent prognostic value for overall survival.
- The genomically annotated MSKCC model demonstrated improved performance in predicting overall survival (C-index 0.637 vs 0.595) and progression-free survival (0.602 vs 0.567) compared to the original model.
- The enhanced model reclassified a significant proportion of patients into different risk groups, with superior performance confirmed in the validation cohort.
Conclusions:
- The mutation status of BAP1, PBRM1, and TP53 provides independent prognostic information in advanced or metastatic renal-cell carcinoma patients treated with first-line tyrosine kinase inhibitors.
- A genomically annotated risk model incorporating these mutations offers improved patient stratification compared to the traditional MSKCC model.
- This enhanced model warrants further investigation in prospective trials for stratifying mRCC patients in clinical settings.
More Related Videos
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
Related Concept Videos
Genome Annotation and Assembly
Genomics
Serum Studies: Renal Function Tests
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Relative Risk
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...